How Much Does Zepbound Cost?

Updated on September 6, 2026 | Written by Alec Pow
This article was researched using 7 sources. See our methodology and corrections policy.

Zepbound can cost anywhere from $25 to more than $1,000 per month in 2026, but the price depends heavily on how you pay for it. Lilly’s current self-pay options start at $299 per month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg under the Zepbound Self Pay Journey Program when its refill conditions are met.

Eligible patients with commercial insurance that covers certain Zepbound prescriptions may pay as little as $25. Eligible Medicare Part D beneficiaries using Zepbound KwikPen for weight management can currently pay $50 per month through the Medicare GLP-1 Bridge. By comparison, the published wholesale acquisition cost for a four-pen supply of the older Zepbound single-dose pens is $1,086.37.

Those prices are not interchangeable. The $449 self-pay price has eligibility and refill requirements, the $25 commercial-insurance price requires qualifying coverage and savings-card eligibility, and the $50 Medicare program has its own clinical criteria.

Article Highlights

• Lilly’s current self-pay price starts at $299 (at $30 per hour, earning that amount would take about 1.2 full-time workdays, before taxes)/month for the 2.5 mg starting dose.
• The 5 mg self-pay price is currently $399/month.
• Eligible self-pay patients can get 7.5, 10, 12.5, or 15 mg for $449/month under the Self Pay Journey Program when refill conditions are met.
• The regular direct price outside that offer can reach $699/month for some higher doses.
• Eligible commercially insured patients with coverage can pay as little as $25 for qualifying single-dose pen prescriptions.
• Eligible Medicare GLP-1 Bridge patients currently pay $50/month for Zepbound KwikPen.
• Paying $449/month instead of the $1,086.37 single-dose-pen list price represents a difference of $637.37 per month.

How Much Does Zepbound Cost?

How Zepbound is purchased	Current price	Main condition
Self-pay 2.5 mg	$299 (about 1.2 full-time workdays at $30 per hour)/month	Current Lilly self-pay pricing
Self-pay 5 mg	$399/month	Current Lilly self-pay pricing
Self-pay 7.5-15 mg	$449/month	Self Pay Journey offer and refill requirements
Regular direct price, 7.5 mg	$499/month	When Journey offer does not apply
Regular direct price, 10-15 mg	$699/month	When Journey offer does not apply
Commercial insurance with qualifying coverage	As little as $25	Eligibility and Savings Card terms apply
Commercial insurance without single-dose pen coverage	As low as $499/month	Eligible Savings Card users
Medicare GLP-1 Bridge	$50/month	Eligible Part D beneficiaries, KwikPen only
Published single-dose pen WAC	$1,086.37/month	Wholesale acquisition cost, not necessarily patient price

Lilly’s current Zepbound affordability page lists self-pay pricing of $299 for 2.5 mg and $399 for 5 mg. Eligible patients using 7.5, 10, 12.5, or 15 mg can pay $449 per 28-day supply through the current Self Pay Journey Program.

The $449 price is not a permanent universal retail price. To continue receiving the Journey offer after the first qualifying higher-dose purchase, the next prescription purchase must generally be completed within 45 days of receiving the previous supply. Lilly says the offer can be changed or terminated.

What You’re Paying For

Zepbound is the brand name for tirzepatide used for FDA-approved chronic weight management in certain adults with obesity or overweight and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Tirzepatide activates both GIP and GLP-1 receptors. Zepbound itself is not the tirzepatide brand approved specifically to treat type 2 diabetes. That product is Mounjaro. Zepbound was first approved by the FDA for chronic weight management on November 8, 2023, and received its additional obstructive sleep apnea indication on December 20, 2024. Current Zepbound strengths are 2.5, 5, 7.5, 10, 12.5, and 15 mg, administered once weekly according to the prescribed dosing schedule.

The FDA’s original Zepbound approval distinguishes it from Mounjaro and confirms the chronic weight-management indication. The FDA later approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.

The $299-$449 Self-Pay Program

The current self-pay structure is much cheaper than the retail figures that dominated Zepbound pricing when the medication first launched.

The 2.5 mg starting dose is currently $299 (about 1.2 full-time workdays at $30 per hour) per month. Lilly specifically notes that 2.5 mg is used for treatment initiation and is not an approved maintenance dose.

The 5 mg dose currently costs $399 per month under Lilly’s self-pay pricing.

Higher strengths of 7.5, 10, 12.5, and 15 mg can cost $449 per month under the Self Pay Journey Program. The first qualifying purchase receives the offer automatically under current program terms. Continued eligibility requires the next purchase within the program’s 45-day refill window.

If that condition is not met, Lilly currently lists regular prices of $499 for 7.5 mg and $699 for 10, 12.5, and 15 mg.

That means missing the Journey condition can make a 15 mg month $250 more expensive:

$699 – $449 = $250.

Across four months at that difference, the extra cost would be $1,000.

The program applies to eligible self-pay purchases through the formats and channels identified by Lilly. Taxes and other fees may apply, and the terms can change.

Commercial Insurance

For patients with commercial drug insurance that covers a qualifying Zepbound single-dose pen prescription, Lilly’s current Zepbound Savings Program can reduce the patient cost to as little as $25 for an eligible one-, two-, or three-month fill.

That does not mean every person with employer or private insurance pays $25. The insurance plan must provide the relevant coverage, the prescription must be for an approved use, and the patient must meet the Savings Program rules. Maximum savings limits also apply.

For eligible commercially insured patients whose plan does not cover the Zepbound single-dose pen, Lilly currently offers a price as low as $499 for a one-month fill.

Patients using self-pay KwikPen pricing may instead qualify for the current $299-$449 structure, depending on dose and program eligibility.

The manufacturer’s commercial Savings Card cannot be used by people enrolled in Medicare, Medicaid, Medigap, VA, TRICARE, or other specified government-funded healthcare programs.

Medicare Now Has a $50 Option

This is one of the largest Zepbound cost changes of 2026. The Centers for Medicare & Medicaid Services launched the Medicare GLP-1 Bridge on July 1, 2026.

Eligible Medicare Part D beneficiaries can obtain certain GLP-1 medications for weight management for a $50 monthly copay. Zepbound is included, but only the KwikPen formulation qualifies under the Bridge. Zepbound single-dose pens and vials are not included.

The program is scheduled to operate through December 31, 2027. The $50 payment is outside the normal Part D benefit payment flow, does not count toward the Part D deductible, and does not count toward TrOOP spending.

Eligibility is not automatic just because someone has Medicare Part D. CMS applies specific clinical and program criteria. Its current provider guidance also distinguishes weight-management Bridge access from GLP-1 use for conditions that can already be covered under ordinary Part D rules.

If someone qualified for six monthly Bridge fills from July through December 2026, the medication copays would total:

6 × $50 = $300.

List Price vs What Patients Pay

Lilly’s current published pricing disclosure lists a wholesale acquisition cost of $1,086.37 for a one-month supply of the Zepbound single-dose pens across all six strengths.

Wholesale acquisition cost is not the same thing as the amount every patient pays at a pharmacy. Insurance contracts, pharmacy reimbursement, manufacturer programs, deductibles, coinsurance, and the formulation being dispensed can all change the actual out-of-pocket price.

The difference between the published $1,086.37 pen WAC and the current $449 Journey price is:

$1,086.37 – $449 = $637.37 per month.

That is approximately 59% below the single-dose-pen WAC.

Annualizing those two prices shows how large the gap becomes:

$1,086.37 × 12 = $13,036.44.

$449 × 12 = $5,388.

The difference is $7,648.44 per year. This calculation compares price levels only. It is not a recommended dosing schedule and assumes the same price remained available for every fill.

Three Zepbound Cost Scenarios

Self-pay higher-dose example: a patient who qualifies for the current $449 Self Pay Journey price for 12 consecutive 28-day supplies would spend $5,388. Taxes or other fees could raise the total.

Commercially insured example: an eligible patient whose covered prescription qualifies for the $25 savings price would spend $300 across 12 one-month fills if that price applied every month. Actual annual savings limits and program rules determine the real result.

Medicare Bridge example: an eligible beneficiary paying $50 per month would spend $600 over 12 qualifying monthly supplies. Because the Bridge began July 1, 2026, a person entering at launch could pay a maximum of about $300 for six July-through-December monthly copays in calendar year 2026.

Worked comparison: paying the current $449 self-pay price instead of $699 for 10, 12.5, or 15 mg saves $250 per fill. Over 10 fills, that difference reaches $2,500.

What Can Change Your Price

Formulation matters. Zepbound is now available through different delivery formats, including single-dose pens, single-dose vials, and KwikPen. Not every savings program covers every format.

Insurance coverage matters. A plan that covers Zepbound can leave one patient paying a low copay while another plan may exclude weight-management drugs or require prior authorization.

Dose can affect self-pay cost. Under the current program, 2.5 mg costs $299, 5 mg costs $399, and qualifying higher doses can cost $449. The price should never be used as a reason to change the prescribed dose or injection frequency.

Refill timing matters. Current higher-dose Journey pricing requires qualifying refills within 45 days. Missing that window can result in the regular program price.

Government coverage follows different rules. Medicare and Medicaid patients cannot use Lilly’s commercial savings card, while Medicare now has the separate GLP-1 Bridge for eligible weight-management patients.

There is no generic Zepbound. Tirzepatide remains a branded prescription medication, so there is no FDA-approved generic Zepbound price to compare with the branded product.

What to Check Before Paying

Makes sense to check:

• Whether your insurance formulary covers Zepbound for the indication on your prescription.
• Whether prior authorization is required.
• Which Zepbound formulation your prescription specifies.
• Whether you meet Lilly’s current commercial or self-pay program conditions.
• Whether Medicare GLP-1 Bridge eligibility applies if you have Part D coverage.

Do not cut costs by:

• Taking Zepbound less often than prescribed.
• Changing dose solely because a different strength has a lower advertised price.
• Combining manufacturer discounts that are not allowed to be stacked.
• Assuming a coupon found online overrides Medicare, Medicaid, or other program rules.

For related pricing comparisons, see our guides to weight loss injection costs, Ozempic costs, and Red Mountain Weight Loss costs.

Current Safety and Storage Facts

Zepbound is prescribed once weekly. It should not be taken every other week or on another self-designed schedule merely to reduce cost.

The current Lilly instructions say a Zepbound single-dose pen may be stored at room temperature up to 86°F for as long as 21 days. If the pen has been stored at room temperature, Lilly says not to return it to the refrigerator.

There is no blanket manufacturer instruction telling every Zepbound patient to avoid NSAIDs such as ibuprofen. The current prescribing information instead highlights issues such as the risk of hypoglycemia when Zepbound is used with insulin or insulin-secretagogue medications, delayed absorption of some oral medications, and monitoring for medications with a narrow therapeutic index such as warfarin.

Lilly also warns that oral birth-control pills may be less effective for four weeks after Zepbound is started and for four weeks after each dose increase. Patients should discuss their medication list and contraception with the prescribing clinician rather than stopping or changing medications independently. Current patient instructions are available on Lilly’s Zepbound use and safety page.

What We Checked

• Checked Lilly’s September 2026 self-pay terms and confirmed current prices of $299, $399, and $449.
• Verified that the higher-dose $449 Self Pay Journey offer uses a 45-day refill condition.
• Confirmed the current published Zepbound single-dose-pen wholesale acquisition cost of $1,086.37.
• Verified the commercial-insurance Savings Program price of as little as $25 for eligible covered prescriptions.
• Checked CMS guidance confirming the Medicare GLP-1 Bridge began July 1, 2026 with a $50 monthly copay for eligible patients.
• Confirmed Zepbound’s November 2023 weight-management approval, December 2024 OSA approval, six current dose strengths, and once-weekly administration.

Answers to Common Questions

How much does Zepbound cost without insurance?
Lilly’s current self-pay pricing starts at $299 per month for 2.5 mg and $399 for 5 mg. Eligible patients using 7.5 through 15 mg can pay $449 per month under the current Self Pay Journey Program when its refill requirements are met.

How much is Zepbound with insurance?
It depends on the plan. Eligible commercially insured patients with qualifying Zepbound coverage may pay as little as $25 under Lilly’s Savings Program. Other patients may owe a deductible, coinsurance, copay, or the full noncovered price.

How much does Zepbound cost with Medicare?
Eligible Medicare Part D beneficiaries using Zepbound KwikPen for qualifying weight management can currently pay $50 per month through the Medicare GLP-1 Bridge. Eligibility rules apply.

What is Zepbound’s list price?
Lilly currently publishes a wholesale acquisition cost of $1,086.37 for a one-month pack of four Zepbound single-dose pens. WAC is not necessarily the amount a patient pays.

Does a higher Zepbound dose always cost more?
No. Under the current Self Pay Journey Program, eligible 7.5, 10, 12.5, and 15 mg supplies can all cost $449 per month.

Is Zepbound approved for diabetes?
Zepbound is not the tirzepatide brand approved specifically to treat type 2 diabetes. Zepbound is approved for chronic weight management in qualifying adults and for moderate-to-severe obstructive sleep apnea in adults with obesity. Tirzepatide is sold under the Mounjaro brand for type 2 diabetes.

How long can Zepbound stay out of the refrigerator?
Current Lilly instructions say a single-dose pen can remain at room temperature up to 86°F for up to 21 days. Follow the storage instructions for the specific Zepbound device you receive.

Can I take Zepbound every other week to save money?
Zepbound is prescribed for once-weekly administration. Do not change the injection schedule to reduce cost without instructions from the prescribing clinician.